Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Lenvatinib + HAIC for Biliary Tract Cancer
NCT06389500Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University
- Start
- May 2024
- Primary completion
- May 2027
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in biliary tract cancer (BTC), sponsored by Harbin Medical University. Primary endpoints: R0 resection rate at 24 months and Surgery conversion rate at 24 months. Planned start May 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06389500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389500.